Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation

NCT00144703 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

55

Enrollment

OTHER

Sponsor class

Conditions

Hematologic Malignancies
Myelogenous Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome
Non-Hodgkin's Lymphoma
Hodgkin's Disease

Interventions

DRUG: Sirolimus
DRUG: Tacrolimus

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]